lamotrigine
Suppliers
Names
[ CAS No. ]:
84057-84-1
[ Name ]:
lamotrigine
[Synonym ]:
Lamictal
Lamotrigin
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine
EINECS 281-901-8
6-(2,3-Dichlorophenyl)-3-imino-3,4-dihydro-1,2,4-triazin-5-amine
1,2,4-Triazin-5-amine, 6-(2,3-dichlorophenyl)-3,4-dihydro-3-imino-
Crisomet
Lamictal CD
HYDROXYMETHYL PROGESTERONE
6-O-TRITYL-1,2,3,4-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSE
BW 430C
LAMOTRIGENE
LAMOTRIGINE API
MFCD00865333
LAMOTRIGINE / 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE-3,5-DIAMINE
Lamictal XR
1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-
LAMOTRIGINE-13C3
LAMOTRIGINE (10 MG )
Lamotrigina
1,2,4-TRIAZINE-3,5-DIAMINE,6-(2,3-DICHLOROPHENYL)-
Labileno
Lamotriginum
Lamotrigine
Chemical & Physical Properties
[ Density]:
1.6±0.1 g/cm3
[ Boiling Point ]:
503.1±60.0 °C at 760 mmHg
[ Melting Point ]:
177-181°C
[ Molecular Formula ]:
C9H7Cl2N5
[ Molecular Weight ]:
256.091
[ Flash Point ]:
258.1±32.9 °C
[ Exact Mass ]:
255.007858
[ PSA ]:
90.71000
[ LogP ]:
-0.19
[ Vapour Pressure ]:
0.0±1.3 mmHg at 25°C
[ Index of Refraction ]:
1.706
[ Storage condition ]:
2-8°C
[ Water Solubility ]:
DMSO: 20 mg/mL at 60 °C, soluble
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- XY5850700
- CHEMICAL NAME :
- 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-
- CAS REGISTRY NUMBER :
- 84057-84-1
- LAST UPDATED :
- 199706
- DATA ITEMS CITED :
- 4
- MOLECULAR FORMULA :
- C9-H7-Cl2-N5
- MOLECULAR WEIGHT :
- 256.11
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 19 mg/kg
- TOXIC EFFECTS :
- Behavioral - muscle contraction or spasticity Sense Organs and Special Senses (Eye) - effect, not otherwise specified Cardiac - EKG changes not diagnostic of specified effects
- REFERENCE :
- LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 342,1552,1993
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 2 mg/kg/30H-I
- TOXIC EFFECTS :
- Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
- REFERENCE :
- PEDIAU Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948- Volume(issue)/page/year: 98,294,1996
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 205 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- EPILAK Epilepsia (New York). (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) Ser.1-3: 1909-55; Ser.4: V.1- 1959- Volume(issue)/page/year: 25,655,1984
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 245 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- EPILAK Epilepsia (New York). (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) Ser.1-3: 1909-55; Ser.4: V.1- 1959- Volume(issue)/page/year: 25,655,1984
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301
[ Precautionary Statements ]:
P301 + P310
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
[ Hazard Codes ]:
T: Toxic;
[ Risk Phrases ]:
R25
[ Safety Phrases ]:
S45
[ RIDADR ]:
UN 2811 6.1/PG 3
[ WGK Germany ]:
3
[ RTECS ]:
XY5850700
[ Packaging Group ]:
III
[ Hazard Class ]:
6.1(b)
[ HS Code ]:
2933699090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2933699090
[ Summary ]:
2933699090 other compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:20.0%
Articles
PLoS ONE 10(1) , e0116766, (2015)
Acute and chronic pain conditions are often debilitating, inflicting severe physiological, emotional and economic costs and affect a large percentage of the global population. However, the development...
J. Pharm. Biomed. Anal. 102 , 25-32, (2014)
A sensitive and accurate gas chromatography-mass spectrometric method was developed and validated for the simultaneous determination of levetiracetam and lamotrigine in whole blood. A solid-phase extr...
Biomaterials 74 , 64-76, (2015)
Despite optimal therapeutic regimen with currently available antiepileptic drugs (AEDs), approximately a third of epilepsy patients remain drug refractory. Region-specific overexpression of multidrug ...